A股異動 | 太安堂漲4.77% 被列入疫情防控重點物資生產及配套企業
格隆匯2月13日丨太安堂(002433.SZ)漲4.77%,報5.05元,總市值38.72億元。

太安堂昨日公佈,經廣東省新型冠狀病毒感染的肺炎疫情防控指揮部物資保障一組批覆【粵物資保障2020-145號】,公司被列入廣東省新型冠狀病毒感染的肺炎疫情防控重點物資生產及配套企業復工復產名單。
此次防治新型冠狀病毒肺炎的過程中,中醫、中藥全程參與此次疫情的防治工作,全程發揮作用,彰顯了中醫藥的特色和優勢。公司的解熱消炎膠囊源自古代治瘟疫病經典方,公司將加快以該品種為主的疫情防控相關的中成藥品種及抗菌消毒用品的生產,滿足市場需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.